Trump, Pharma and Blow Up
Digest more
Top News
Reactions and opinions
Drugmakers are lobbying U.S. President Donald Trump to phase in tariffs on imported pharmaceutical products in hopes of reducing the sting from the charges and to allow time to shift manufacturing, a...
From Reuters
Stocks dived on Thursday and investors scrambled for the safety of bonds, gold and the yen, fearing new U.S. tariffs have intensified a trade war threatening to tip the world into recession.
From Reuters
Read more on News Digest
In pharma, buying software (instead of building) means working with industry professionals who can develop solutions to meet their needs—even before they realize they have them.
A little over a year after winning manufacturing certification for its cell therapy factory-in-a-box, South San Francisco’s Cellares has passed another major production milestone. | Cellares’ automated cell therapy production platform,
Streeting said his June 10-year plan will address drug sale clawbacks, NICE regulation, and the abolition of NHS England.
China’s draft pharmaceutical trial rules aim to balance innovation with drug availability; CAC issues first rules to regulate facial recognition technology; and UBS becomes the 5th wholly foreign-owned securities firm in China.
1d
Zacks Investment Research on MSNDuPont Introduces Liveo Pharma TPE Ultra-Low Temp TubingDuPont de Nemours, Inc. DD recently announced the launch of its Liveo Pharma TPE Ultra-Low Temp Tubing, a new thermoplastic elastomer tubing. This product has been designed keeping in mind the ability required to withstand low temperatures in many biopharmaceutical processing applications.
The total number of gross (or "theoretical") voting rights is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached,
The session highlighted existing policy support mechanisms and upcoming opportunities under the PRIP scheme aimed at fostering a robust innovation pipeline in India.
The Nifty 50, which started the session with sharp losses, erased most of them as the day progressed, ending at 23,243 points, down 0.38% from the previous close. Meanwhile, the Sensex closed 0.42% lower at 76,
In addition to its proprietary Amanitin-based ADC technology, Heidelberg Pharma has developed a diverse ADC toolbox designed to overcome tumor resistance through multiple mechanisms, enabling targeted treatment across various cancer types. Dr. Sarah-Jane ...